1. Clinical & Scientific Overview
Pethidine Hydrochloride (Meperidine) (TIP-MED-000522, Reference Code [R-03]) is classified under
Narcotic Analgesics (NDPS Controlled) as a Synthetic Phenylpiperidine Mu-Opioid Agonist.
Within the Indian regulatory and compendial framework, it is governed under NDPS Act, 1985 Narcotic Drug & Schedule X / H1.
Pethidine HCl Injection (Verve Health Care), Pethitroy (Troikaa Pharmaceuticals)
Injection: 50 mg/mL (1 mL and 2 mL ampoules)
Statutory Restriction, High-Alert & Dispensing Safeguards
Indian Regulatory & Statutory Control Basis: NDPS Act, 1985 Narcotic Drug & Schedule X / H1
High-Alert Clinical Risk, Dependence & Narrow Therapeutic Index Warnings: Hepatic N-demethylation generates normeperidine (t1/2 15–30 h), a neurotoxic metabolite that accumulates in renal impairment and triggers myoclonus and generalized seizures; contraindicated with MAO inhibitors (fatal serotonin syndrome).
Mandatory Dispensing Register & Institutional Custody Protocol: Strict double-lock narcotic register tracking ampoule serial numbers, wastage witness signatures, and maximum 48-hour duration.
3. Mechanism of Action & Pharmacodynamics
Full mu-opioid receptor agonist inhibiting ascending nociceptive transmission in the dorsal horn and periaqueductal grey.
4. Therapeutic Indications & Evidence-Supported Uses
- Acute severe perioperative and labour analgesia (short-term hospital use only)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Specialist-Supervised Educational Reference Summary: Dosing of Pethidine must be individualised by a qualified specialist according to clinical indication, organ function, and institutional protocol (Injection: 50 mg/mL (1 mL and 2 mL ampoules)).
Administration & Meal Timing: Routes: Intramuscular, Slow Intravenous, Subcutaneous. Strict double-lock narcotic register tracking ampoule serial numbers, wastage witness signatures, and maximum 48-hour duration.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Exhibits synthetic phenylpiperidine mu-opioid agonist pharmacokinetic disposition; verify baseline renal and hepatic clearance and check for active or prolonged-half-life metabolites before repeat dosing.
Hepatic Phase I (CYP450) and/or Phase II conjugation or specific non-renal clearance as detailed in clinical warnings.
Verify eGFR / CrCl before initiation; see specific metabolite and renal clearance notes above.
Assess baseline Child-Pugh status and hepatic transaminases prior to therapy.
7. Contraindications, Precautions & High-Risk Warnings
- Known severe hypersensitivity to Pethidine or formulation excipients
- Unsupervised outpatient self-administration or dispensing without mandatory statutory prescription verification
- Specific clinical contraindications detailed under High-Alert Warnings & Statutory Restrictions
Key Clinical Precautions: Hepatic N-demethylation generates normeperidine (t1/2 15–30 h), a neurotoxic metabolite that accumulates in renal impairment and triggers myoclonus and generalized seizures; contraindicated with MAO inhibitors (fatal serotonin syndrome).
8. Adverse Effects Profile
- Hepatic N-demethylation generates normeperidine (t1/2 15–30 h), a neurotoxic metabolite that accumulates in renal impairment and triggers myoclonus and generalized seizures; contraindicated with MAO inhibitors (fatal serotonin syndrome).
- Dose-dependent target-organ pharmacodynamic effects requiring clinical observation
- Hepatic N-demethylation generates normeperidine (t1/2 15–30 h), a neurotoxic metabolite that accumulates in renal impairment and triggers myoclonus and generalized seizures; contraindicated with MAO inhibitors (fatal serotonin syndrome).
- High-alert toxicity, dependence/diversion risk, or severe organ-specific adverse events if administered outside protocol
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Hepatic N-demethylation generates normeperidine (t1/2 15–30 h), a neurotoxic metabolite that accumulates in renal impairment and triggers myoclonus and generalized seizures; contraindicated with MAO inhibitors (fatal serotonin syndrome).
- Review all concomitant CNS depressants, QTc-prolonging agents, nephrotoxins, or CYP450 modulators prior to dispensing.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Strict double-lock narcotic register tracking ampoule serial numbers, wastage witness signatures, and maximum 48-hour duration.
Pharmacist Patient Counselling Points:
- Strict double-lock narcotic register tracking ampoule serial numbers, wastage witness signatures, and maximum 48-hour duration.
- Must be used strictly under direct medical supervision; never share prescription medicines or alter the prescribed dose.
Storage, Stability & Dispensing Safeguards: Strict double-lock narcotic register tracking ampoule serial numbers, wastage witness signatures, and maximum 48-hour duration.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Drugs and Cosmetics Act, 1940 & Rules, 1945 (Schedule H / H1 / X); NDPS Act, 1985 & Essential Narcotic Drugs (END) Notification; Indian Pharmacopoeia (IP) & National Formulary of India (NFI).
Official Verification Portals: CDSCO — Drugs & Cosmetics Act and Rules (Schedules H, H1, X) • Department of Revenue — Narcotic Drugs and Psychotropic Substances (NDPS) Act • Indian Pharmacopoeia Commission (IPC) — National Formulary of India
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [R-04] Methadone Hydrochloride — Synthetic Long-Acting Mu-Opioid Agonist & NMDA Antagonist
- [R-05] Codeine Phosphate — Phenanthrene Opioid Agonist & Central Antitussive
- [R-01] Buprenorphine (Sublingual & Transdermal) — Partial Mu-Opioid Agonist & Kappa-Opioid Antagonist
- [R-02] Pentazocine Lactate / Hydrochloride — Mixed Opioid Agonist-Antagonist Analgesic
